Search results for: Precision Medicine
Filter search results
OHE’s Paula Lorgelly Appointed as a Visiting Professor at King’s College London
20 June 2016
Paula Lorgelly has accepted an appointment as a Visiting Professor in the Division of Cancer Studies at King’s College London. Paula Lorgelly, OHE’s Deputy Director, has been appointed as a…
Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies
1 January 2022
A paradigm shift is occurring in cancer care with the introduction of tumour-agnostic therapies, for which the indication is defined by the molecular signature of the tumour rather than by…
OHE Lunchtime Seminar: Health Technology Assessment Scientific and Outcomes Advice on Medicinal Drug Development
4 October 2016, 11:00pm
…(Medicines and Healthcare products Regulatory Agency, MHRA, and European Medicines Agency, EMA). Despite these efforts HTA SA is not routinely integrated into the clinical development of new medicines and it…
Around The World in HTAs: Greece – Late but with an Optimistic Future
18 October 2023
…users’ private spending making up the remaining 38% (Hellenic Statistical Authority (ELSTAT), 2023). The HTA process framework The value assessments of medicines and medical devices are managed separately. Assessment of medicines …
The WHO Technical Report on the Pricing of Cancer Medicines: Missing a central role for HTA and value assessment
1 April 2019
The WHO Technical Report: Pricing of cancer medicines and its impacts (“the Report”) was published in order to address requests made in a resolution adopted by the 2018 Seventieth World…
OHE at AES: Medicines Prices in the UK, Health Inequalities in Costa Rica
25 June 2013
…recent research on projecting medicines expenditures in the NHS using a bottom-up, rather than a top-down, approach. OHE’s participation at the 33rd Meeting of the Spanish Health Economics Association (AES)…
Defining Innovation in Medicines and Transforming it into Value
3 July 2013
…of key European countries to valuing innovation in medicines and explained how actions by payers can affect the rate and direction of innovation. Defining Innovation in Medicines: How to Transform…
The Future of Global Health Procurement: Issues around Pricing Transparency
1 March 2019
…of medicines by Middle and Low Income Countries. Will making prices publicly available make procurement more efficient and cost-effective medicines more accessible? This OHE Research Paper focuses on the role…
Is collaboration between and across regulatory and HTA agencies the answer to access challenges?
12 November 2024
…timely development of medicines and provide earlier patient access to truly innovative medicines, by pulling together expertise from across the MHRA and partners in the wider healthcare system including NICE,…